Ionis Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 43.52 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.23B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ...